当心！你的身体可能正被"第四高"偷袭！关节肿痛、莫名不适...这些也许是身体发出的尿酸超标信号！如何避开高尿酸"陷阱"？本期节目为你带来“高尿酸4大元凶+科学应对方案”全解析，守护健康刻不容缓！

Make sure to check outAndrás' Skeptics in the Pub Online talknext week on 25 September! In TWISH we meetÖtzi the Ice Man, and a mystery death from 5300 years ago and a invaluable source of archeological science. Then we look to the news:ALBANIA: Albania appoints AI-created ‘minister’ITALY: Arson attack in Sardinia linked to climate misinformationSWEDEN: Princess Madeleine launches her brand of Weleda based cosmeticsAUSTRIA: Nominations now open for the Golden Board 2025SWITZERLAND: Switzerland

Human-Centered Conflict Resolution: The Key to Personal and Collective Flourishing

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Vladimir Tesar Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Kenneth Lieberman, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Meghan Sise, MD Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS care.

Faculty: Kenneth Lieberman, MD Faculty: Vladimir Tesar Managing patients with focal segmental glomerulosclerosis, or FSGS, can present certain challenges. FSGS is a serious, progressive condition that has no current FDA-approved treatment and standard of care therapy may not meet treatment goals for many patients. But the current use of patient-reported outcomes (PROs), as well as emerging treatments on the horizon, may prove to be valuable tools in shaping the future of FSGS

Élèves et enseignants ont repris le chemin de l’école. Une petite nouvelle s’invite de plus en plus avec eux : l’intelligence artificielle (IA) dite « générative ». Quelle place faut-il lui accorder? C’est le sujet de notre émission cette semaine.

CAR-T 细胞疗法是近年来抗癌领域的重大突破，其原理是通过基因工程改造患者自身 T 细胞，使其表达能识别癌细胞表面抗原的嵌合抗原受体（CAR），从而精准攻击肿瘤细胞。

今天有个非常重要的消息告诉大家，9月份是全国科普月，中国青少年科技教育工作者协会正在发起科普兴邦、银幕启智，科学家精神进校园，科普电影公益放映活动，这次活动，中青教协选择了由我编剧导演的科普电影《寻秘自然：地球往事》作为这次公映放映活动的唯一指定电影。无独有偶，上海市教委体卫艺科处指导下的上海市中小学“科普校园行”活动组委会也在9月份开展科学星光筑梦未来的科普电影进校园活动，也选择了我的科普电影《寻秘自然：地球往事》向全上海市的中小学推广。这两个活动都是公益性质的，只要您是学校，不管是中小学还是职高、大学，或者科博馆，都可以向中青教协或者上海市科普校园行活动组委会申请免费的放映权限。如果您想报名，可以关注寻秘自然的微信公号，然后回复关键词“校园放映”，就可以获得报名详情。也欢迎大家转发这个消息给亲朋好友，一起助力传播科学精神。

Puedes escuchar este episodio gratis en iVoox (https://www.ivoox.com/podcast-coffee-break-senal-ruido_sq_f1172891_1.html) o en cualquier otra app apoyándonos en iVoox o Spotify.El spin-off de Coffee Break: Señal y Ruido -Lore ganimediano (1:00) -Legio Nona: La legión romana que desapareció (10:00) -Preguntas y Respuestas: Tiempos de dos dimensiones (29:15)

Listen to 130 Future Now ShowThis week we havegeopolitical concerns, and criticize legacy media calls for war. We thenexplore theories ofquantum consciousnessand reality splits. We then focus oncelestial eventslike the interstellar comet 3I/ATLAS, along with the threat of asteroids, which leads to a discussion aboutspace exploration and militarization, contrasting NASA’s historical role with the newly formed Space Force. Our conversation also touches on the latest onextraterrestrial lifeon

From carrot flowers to potting soil made of concrete waste – could local, organic and eco-friendly bouquets be the future of floristry? In France, nine out of 10 flowers are imported, but that's starting to change. After decades of being overshadowed by the Netherlands, fierce global competition and strict regulations, the country's flower industry is bouncing back. We met with French florists, farmers and scientists who are behind a blooming revolution to revive "les fleurs françaises".

In this short podcast, recorded on a hot day in mid August, we discuss heat stroke in dogs in hot weather, the link between ear disease and swimming and how to help a dog terrified of going up stairs, a cat that's started howling at night.

Charlie Boocock-Yee, a Masters student in Zoology, studies the ear bones of fossilised fish to find out about their lives.Broadcast on OAR 105.4FM Dunedin www.oar.org.nz